Boehringer Scores First Approval For Targeted Oral Drug In HER2-Mutant NSCLC

But Bayer Has One Under FDA Review

 
• By Alaric DeArment
  
Boehringer Ingelheim
• Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip